0.01%阿托品滴眼液控制近视发展的临床进展

Clinical Progress of 0.01% Atropine Eye Drops in Controlling the Development of Myopia

近些年来,随着各种电子产品的普及以及学业的日渐繁重,青少年长时间不恰当的用眼习惯,青春期又处于视觉系统发育的重要阶段,使得近视的发生年龄逐年下降,近视已经成为了影响中国乃至全世界青少年生理与心理健康的重要影响因素。在近视的发病率的研究中,青少年组的数据尤其引人关注。近些年来,医学界乃至与国家层面,注重青少年的近视发展,防止其进展为高度近视,从而减少高度近视带来的一系列不良后果。目前,减缓青少年近视进展的方法众多,其中角膜塑形镜是这方面的热点。随着人们对近视防控研究的深入,0.01%阿托品滴眼液控制近视发展的效果也值得世界认可。本文主要就目前0.01%阿托品滴眼液延缓青少年近视发展的机制和目前的研究成果进行综述。

In recent years, with the popularity of various electronic products and the increasingly heavy academic problems, teenagers have long improper eye use habits, and adolescence is in an important stage of visual system development, which makes the age of myopia decline year by year. Myopia has become an important factor affecting the physical and mental health of teenagers in China and even the world. In the study of the incidence rate of myopia, the data of the adolescent group are particularly interesting. In recent years, the medical community and even the national level, pay attention to the development of juvenile myopia, prevent its progress to high myopia, so as to reduce a series of adverse consequences of high myopia. At present, there are many ways to slow down the progress of juvenile myopia, among which orthokeratology is a hot spot. With the in-depth study of myopia prevention and control, the effect of 0.01% atropine eye drops on myopia development is also worthy of world recognition. This article mainly reviews the mechanism and current research results of 0.01% atropine eye drops in delaying the development of juvenile myopia.